Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas.
Sophie SchneiderThomas FerteOcéane DucharmeLéa DoussetSorilla PreyCaroline DutriauxEmilie GerardMarie Beylot-BarryAnne Pham-LedardPublished in: Journal of cancer research and clinical oncology (2024)
Patients with acSCC are usually very frail and elderly. OS increased over time, with a twofold improvement between periods 1 and 2, whereas progression-free survival (PFS) did not increase. Access to immunotherapy reduced mortality in a majority of patients in period 2. Immunosuppression and advanced age were associated with lower PFS.